Experimental combo aims to outsmart Drug-Resistant lung cancer

NCT ID NCT02503722

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated Jun 13, 2026 · Updated 35 times

Summary

This early-phase trial tests a new two-drug combination (sapanisertib and osimertinib) in 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatment. The main goal is to find the safest dose and identify side effects. This is not a cure; it aims to control the disease by blocking cancer growth signals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

BCCA-Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Yale University

New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.